A citation-based method for searching scientific literature

Felicia Cosman, Daria B Crittenden, Jonathan D Adachi, Neil Binkley, Edward Czerwinski, Serge Ferrari, Lorenz C Hofbauer, Edith Lau, E Michael Lewiecki, Akimitsu Miyauchi, Cristiano A F Zerbini, Cassandra E Milmont, Li Chen, Judy Maddox, Paul D Meisner, Cesar Libanati, Andreas Grauer. N Engl J Med 2016
Times Cited: 575







List of co-cited articles
771 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis.
Kenneth G Saag, Jeffrey Petersen, Maria Luisa Brandi, Andrew C Karaplis, Mattias Lorentzon, Thierry Thomas, Judy Maddox, Michelle Fan, Paul D Meisner, Andreas Grauer. N Engl J Med 2017
423
60

Romosozumab in postmenopausal women with low bone mineral density.
Michael R McClung, Andreas Grauer, Steven Boonen, Michael A Bolognese, Jacques P Brown, Adolfo Diez-Perez, Bente L Langdahl, Jean-Yves Reginster, Jose R Zanchetta, Scott M Wasserman,[...]. N Engl J Med 2014
654
39

Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial.
Bente L Langdahl, Cesar Libanati, Daria B Crittenden, Michael A Bolognese, Jacques P Brown, Nadia S Daizadeh, Eva Dokoupilova, Klaus Engelke, Joel S Finkelstein, Harry K Genant,[...]. Lancet 2017
156
26

Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial.
Paul D Miller, Gary Hattersley, Bente Juel Riis, Gregory C Williams, Edith Lau, Luis Augusto Russo, Peter Alexandersen, Cristiano A F Zerbini, Ming-yi Hu, Alan G Harris,[...]. JAMA 2016
350
23

Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.
R M Neer, C D Arnaud, J R Zanchetta, R Prince, G A Gaich, J Y Reginster, A B Hodsman, E F Eriksen, S Ish-Shalom, H K Genant,[...]. N Engl J Med 2001
22

A Phase III Randomized Placebo-Controlled Trial to Evaluate Efficacy and Safety of Romosozumab in Men With Osteoporosis.
E Michael Lewiecki, Tomasz Blicharski, Stefan Goemaere, Kurt Lippuner, Paul D Meisner, Paul D Miller, Akimitsu Miyauchi, Judy Maddox, Li Chen, Stephane Horlait. J Clin Endocrinol Metab 2018
83
21

Denosumab for prevention of fractures in postmenopausal women with osteoporosis.
Steven R Cummings, Javier San Martin, Michael R McClung, Ethel S Siris, Richard Eastell, Ian R Reid, Pierre Delmas, Holly B Zoog, Matt Austin, Andrea Wang,[...]. N Engl J Med 2009
17

Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial.
David L Kendler, Fernando Marin, Cristiano A F Zerbini, Luis A Russo, Susan L Greenspan, Vit Zikan, Alicia Bagur, Jorge Malouf-Sierra, Péter Lakatos, Astrid Fahrleitner-Pammer,[...]. Lancet 2018
180
17

Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody.
Desmond Padhi, Graham Jang, Brian Stouch, Liang Fang, Edward Posvar. J Bone Miner Res 2011
523
16

Effects of 24 Months of Treatment With Romosozumab Followed by 12 Months of Denosumab or Placebo in Postmenopausal Women With Low Bone Mineral Density: A Randomized, Double-Blind, Phase 2, Parallel Group Study.
Michael R McClung, Jacques P Brown, Adolfo Diez-Perez, Heinrich Resch, John Caminis, Paul Meisner, Michael A Bolognese, Stefan Goemaere, Henry G Bone, Jose R Zanchetta,[...]. J Bone Miner Res 2018
74
20

One Year of Romosozumab Followed by Two Years of Denosumab Maintains Fracture Risk Reductions: Results of the FRAME Extension Study.
E Michael Lewiecki, Rajani V Dinavahi, Marise Lazaretti-Castro, Peter R Ebeling, Jonathan D Adachi, Akimitsu Miyauchi, Evelien Gielen, Cassandra E Milmont, Cesar Libanati, Andreas Grauer. J Bone Miner Res 2019
57
24

Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.
Dennis M Black, Pierre D Delmas, Richard Eastell, Ian R Reid, Steven Boonen, Jane A Cauley, Felicia Cosman, Péter Lakatos, Ping Chung Leung, Zulema Man,[...]. N Engl J Med 2007
13

Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial.
Benjamin Z Leder, Joy N Tsai, Alexander V Uihlein, Paul M Wallace, Hang Lee, Robert M Neer, Sherri-Ann M Burnett-Bowie. Lancet 2015
219
13

Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein.
M E Brunkow, J C Gardner, J Van Ness, B W Paeper, B R Kovacevich, S Proll, J E Skonier, L Zhao, P J Sabo, Y Fu,[...]. Am J Hum Genet 2001
667
13

10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension.
Henry G Bone, Rachel B Wagman, Maria L Brandi, Jacques P Brown, Roland Chapurlat, Steven R Cummings, Edward Czerwiński, Astrid Fahrleitner-Pammer, David L Kendler, Kurt Lippuner,[...]. Lancet Diabetes Endocrinol 2017
309
12

Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures.
J A Kanis, N C Harvey, E McCloskey, O Bruyère, N Veronese, M Lorentzon, C Cooper, R Rizzoli, G Adib, N Al-Daghri,[...]. Osteoporos Int 2020
71
16

Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST).
W Balemans, M Ebeling, N Patel, E Van Hul, P Olson, M Dioszegi, C Lacza, W Wuyts, J Van Den Ende, P Willems,[...]. Hum Mol Genet 2001
775
11


Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.
Charles H Chesnut, Arne Skag, Claus Christiansen, Robert Recker, Jacob A Stakkestad, Arne Hoiseth, Dieter Felsenberg, Hermann Huss, Jennifer Gilbride, Ralph C Schimmer,[...]. J Bone Miner Res 2004
763
10

Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Guideline Update.
Dolores Shoback, Clifford J Rosen, Dennis M Black, Angela M Cheung, M Hassan Murad, Richard Eastell. J Clin Endocrinol Metab 2020
62
16


Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators.
B Ettinger, D M Black, B H Mitlak, R K Knickerbocker, T Nickelsen, H K Genant, C Christiansen, P D Delmas, J R Zanchetta, J Stakkestad,[...]. JAMA 1999
9

Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation.
Kenneth E S Poole, Rutger L van Bezooijen, Nigel Loveridge, Herman Hamersma, Socrates E Papapoulos, Clemens W Löwik, Jonathan Reeve. FASEB J 2005
596
9


Increased bone mineral density for 1 year of romosozumab, vs placebo, followed by 2 years of denosumab in the Japanese subgroup of the pivotal FRAME trial and extension.
Akimitsu Miyauchi, Rajani V Dinavahi, Daria B Crittenden, Wenjing Yang, Judy C Maddox, Etsuro Hamaya, Yoichi Nakamura, Cesar Libanati, Andreas Grauer, Junichiro Shimauchi. Arch Osteoporos 2019
17
52

Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength.
Xiaodong Li, Michael S Ominsky, Qing-Tian Niu, Ning Sun, Betsy Daugherty, Diane D'Agostin, Carole Kurahara, Yongming Gao, Jin Cao, Jianhua Gong,[...]. J Bone Miner Res 2008
634
9

Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis.
Xiaodong Li, Michael S Ominsky, Kelly S Warmington, Sean Morony, Jianhua Gong, Jin Cao, Yongming Gao, Victoria Shalhoub, Barbara Tipton, Raj Haldankar,[...]. J Bone Miner Res 2009
555
9

Bone-Forming and Antiresorptive Effects of Romosozumab in Postmenopausal Women With Osteoporosis: Bone Histomorphometry and Microcomputed Tomography Analysis After 2 and 12 Months of Treatment.
Pascale Chavassieux, Roland Chapurlat, Nathalie Portero-Muzy, Jean-Paul Roux, Pedro Garcia, Jacques P Brown, Cesar Libanati, Rogely W Boyce, Andrea Wang, Andreas Grauer. J Bone Miner Res 2019
34
26

Romosozumab FRAME Study: A Post Hoc Analysis of the Role of Regional Background Fracture Risk on Nonvertebral Fracture Outcome.
Felicia Cosman, Daria B Crittenden, Serge Ferrari, E Michael Lewiecki, Juan Jaller-Raad, Cristiano Zerbini, Cassandra E Milmont, Paul D Meisner, Cesar Libanati, Andreas Grauer. J Bone Miner Res 2018
34
26

Fracture Prevention with Zoledronate in Older Women with Osteopenia.
Ian R Reid, Anne M Horne, Borislav Mihov, Angela Stewart, Elizabeth Garratt, Sumwai Wong, Katy R Wiessing, Mark J Bolland, Sonja Bastin, Gregory D Gamble. N Engl J Med 2018
137
8


Two years of Denosumab and teriparatide administration in postmenopausal women with osteoporosis (The DATA Extension Study): a randomized controlled trial.
Benjamin Z Leder, Joy N Tsai, Alexander V Uihlein, Sherri-Ann M Burnett-Bowie, Yuli Zhu, Katelyn Foley, Hang Lee, Robert M Neer. J Clin Endocrinol Metab 2014
151
8

Binding Selectivity of Abaloparatide for PTH-Type-1-Receptor Conformations and Effects on Downstream Signaling.
Gary Hattersley, Thomas Dean, Braden A Corbin, Hila Bahar, Thomas J Gardella. Endocrinology 2016
133
8

Change in Bone Density and Reduction in Fracture Risk: A Meta-Regression of Published Trials.
Mary L Bouxsein, Richard Eastell, Li-Yung Lui, Lucy A Wu, Anne E de Papp, Andreas Grauer, Fernando Marin, Jane A Cauley, Douglas C Bauer, Dennis M Black. J Bone Miner Res 2019
70
11

Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway.
Asiri R Wijenayaka, Masakazu Kogawa, Hui Peng Lim, Lynda F Bonewald, David M Findlay, Gerald J Atkins. PLoS One 2011
290
8

Osteocyte control of bone formation via sclerostin, a novel BMP antagonist.
David G Winkler, May Kung Sutherland, James C Geoghegan, Changpu Yu, Trenton Hayes, John E Skonier, Diana Shpektor, Mechtild Jonas, Brian R Kovacevich, Karen Staehling-Hampton,[...]. EMBO J 2003
707
8

A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density.
Robert R Recker, Charles T Benson, Toshio Matsumoto, Michael A Bolognese, Deborah A Robins, Jahangir Alam, Alan Y Chiang, Leijun Hu, John H Krege, Hideaki Sowa,[...]. J Bone Miner Res 2015
170
8

SOST is a target gene for PTH in bone.
Hansjoerg Keller, Michaela Kneissel. Bone 2005
404
8

SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor.
Mikhail Semënov, Keiko Tamai, Xi He. J Biol Chem 2005
519
8

A bispecific antibody targeting sclerostin and DKK-1 promotes bone mass accrual and fracture repair.
Monica Florio, Kannan Gunasekaran, Marina Stolina, Xiaodong Li, Ling Liu, Barbara Tipton, Hossein Salimi-Moosavi, Franklin J Asuncion, Chaoyang Li, Banghua Sun,[...]. Nat Commun 2016
133
8

Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society* Clinical Practice Guideline.
Richard Eastell, Clifford J Rosen, Dennis M Black, Angela M Cheung, M Hassan Murad, Dolores Shoback. J Clin Endocrinol Metab 2019
192
8

Bone mineral density gains with a second 12-month course of romosozumab therapy following placebo or denosumab.
D L Kendler, H G Bone, F Massari, E Gielen, S Palacios, J Maddox, C Yan, S Yue, R V Dinavahi, C Libanati,[...]. Osteoporos Int 2019
30
26

Evaluating the cardiovascular safety of sclerostin inhibition using evidence from meta-analysis of clinical trials and human genetics.
Jonas Bovijn, Kristi Krebs, Chia-Yen Chen, Ruth Boxall, Jenny C Censin, Teresa Ferreira, Sara L Pulit, Craig A Glastonbury, Samantha Laber, Iona Y Millwood,[...]. Sci Transl Med 2020
24
33

Discontinuation of Denosumab therapy for osteoporosis: A systematic review and position statement by ECTS.
Elena Tsourdi, Bente Langdahl, Martine Cohen-Solal, Bérengere Aubry-Rozier, Erik Fink Eriksen, Nuria Guañabens, Barbara Obermayer-Pietsch, Stuart H Ralston, Richard Eastell, M Carola Zillikens. Bone 2017
203
7

Role and mechanism of action of sclerostin in bone.
Jesus Delgado-Calle, Amy Y Sato, Teresita Bellido. Bone 2017
150
7

Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis.
Felicia Cosman, Erik Fink Eriksen, Chris Recknor, Paul D Miller, Núria Guañabens, Christian Kasperk, Philemon Papanastasiou, Aimee Readie, Hanumantha Rao, Jürg A Gasser,[...]. J Bone Miner Res 2011
206
7

Teriparatide or alendronate in glucocorticoid-induced osteoporosis.
Kenneth G Saag, Elizabeth Shane, Steven Boonen, Fernando Marín, David W Donley, Kathleen A Taylor, Gail P Dalsky, Robert Marcus. N Engl J Med 2007
514
7

Imminent fracture risk.
C Roux, K Briot. Osteoporos Int 2017
86
8

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group.
D M Black, S R Cummings, D B Karpf, J A Cauley, D E Thompson, M C Nevitt, D C Bauer, H K Genant, W L Haskell, R Marcus,[...]. Lancet 1996
7

Treatment Sequence Matters: Anabolic and Antiresorptive Therapy for Osteoporosis.
Felicia Cosman, Jeri W Nieves, David W Dempster. J Bone Miner Res 2017
94
7


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.